Novo Nordisk accuses rival companies of foul play
Competition on the market for insulin is tightening for new as well as old products. Novo Nordisk is locked in an intense price war on new markets and experiences incidents of foul play from other actors.
af LEONORA BECK
It is a battle to the death to win and maintain market shares on the valuable diabetes market. And during the course of that battle competitors are met with unfair methods and persistent price war, according to Danish newspaper Berlingske.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
.jpg&w=384&q=75){kind=logo}
